Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 10/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.37 |
| ▸ | CLPP | Q16740 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22119307 | 0.91 | PDE9A (0.58) | PDE9APIK3CAPIK3CBBRD4KAT2B | |
| SCHEMBL22245169 | 0.89 | PDE9A (0.44) | PDE9APIK3CAPIK3CBTP53 | |
| SCHEMBL22245241 | 0.83 | PDE9A (0.59) | PDE9AP2RX7 | |
| SCHEMBL22119355 | 0.80 | PDE9A (0.59) | PDE9APIK3CAPIK3CBBRD4PDE2A | |
| SCHEMBL22119586 | 0.80 | PDE9A (0.56) | PDE9ABRD4PDE2AFABP4TP53 | |
| SCHEMBL22119185 | 0.79 | PDE9A (0.55) | PDE9ABRD4KAT2BTP53CLPP | |
| SCHEMBL22119161 | 0.79 | — | — | |
| SCHEMBL32665812 | 0.79 | — | — | |
| SCHEMBL22119244 | 0.78 | KDM4C (0.38) | PDE9A | |
| SCHEMBL22119175 | 0.77 | PDE9A (0.42) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | ACURX PHARMACEUTICALS LLC (US) | 2022-04-14 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | PDE9A 2005/4885PIK3CA 103/4885PIK3CB 94/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | PDE9A 2788/4885PIK3CA 830/4885PIK3CB 1138/4885 |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | PDE9A 2025/4885PIK3CA 111/4885PIK3CB 101/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | PDE9A 2005/4885PIK3CA 103/4885PIK3CB 94/4885 |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | PDE9A 2025/4885PIK3CA 111/4885PIK3CB 101/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | PDE9A 2025/4885PIK3CA 111/4885PIK3CB 101/4885 |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | PDE9A 2005/4885PIK3CA 103/4885PIK3CB 94/4885 |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | PDE9A 2025/4885PIK3CA 111/4885PIK3CB 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.